高剂量塞替派辅助治疗可切除复发骨肉瘤的随机II期试验
这项多中心随机开放标签II期研究纳入44例1-50岁可切除复发高级别骨肉瘤患者,按1:1随机接受标准化疗联合高剂量塞替派及自体移植(A组)或单纯标准化疗(B组)。主要终点总生存(OS)无显著改善,2年OS率A组66.7%对B组50.0%,中位OS 27.4对24.8个月(HR 0.826,95%CI 0.393-1.734;P=0.6123),中位无进展生存(PFS)15.6对7.2个月(P=0.3845)。结论为高剂量塞替派不能推荐用于可切除复发骨肉瘤的辅助治疗。
要点
- 高剂量塞替派联合自体移植未显著改善可切除复发骨肉瘤的OS和PFS。
- 2年OS率A组66.7%(95%CI 42.5-82.5)对B组50.0%(95%CI 28.2-68.4),差异无统计学意义。
- 尽管生存有延长趋势且毒性可接受,塞替派仍不能推荐用于该人群。
核心结论
- 辅助高剂量塞替派未能显著改善可切除复发骨肉瘤患者的总生存和无进展生存。
- 尽管观察到生存延长的趋势且毒性可接受,塞替派不能推荐用于该适应症。
研究设计与样本
- 多中心随机开放标签II期临床试验,纳入1-50岁局部或转移性复发高级别骨肉瘤患者。
- 患者经两周期标准化疗未进展且预计可实现完全切除,按1:1随机分配至A组(标准化疗+高剂量塞替派+自体移植)或B组(单纯标准化疗)。
- 主要终点为总生存,次要终点包括无进展生存和安全性。
主要发现
- 2年OS率A组为66.7%(95%CI 42.5-82.5),B组为50.0%(95%CI 28.2-68.4)。
- 中位OS A组27.4个月,B组24.8个月(HR 0.826,95%CI 0.393-1.734;P=0.6123)。
- 中位PFS A组15.6个月(95%CI 8.9-24.9),B组7.2个月(95%CI 4.8-33.3),P=0.3845。
- A组22例中16例(72.7%)发生至少1次≥3级不良事件,B组22例中18例(81.8%),未发生毒性死亡。
临床怎么用
- 对于可切除的复发高级别骨肉瘤,不推荐在标准化疗基础上常规联合高剂量塞替派及自体移植。
- 临床决策应继续以标准化疗和完全手术切除为核心,高剂量塞替派仅限研究背景下考虑。
局限性
- 样本量较小(共44例),可能不足以检测出统计学显著的生存差异。
- 研究为开放标签设计,可能存在偏倚。
- 随访时间和事件数有限,长期生存获益未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of high-dose chemotherapy in relapsing osteosarcomas has not been established. We evaluated the efficacy and tolerance of high-dose thiotepa (HDTp) after standard chemotherapy (SCT) in patients with relapsed osteosarcoma. PATIENTS AND METHODS: This randomised open-label phase II study enrolled patients 1-50 years, with local or metastatic relapse of a high-grade osteosarcoma, not progressive after two cycles of SCT, for whom a complete surgery can be achievable following treatment. The trial assigned enrolled patients in a 1:1 ratio to receive two additional courses of SCT + HDTp and autologous transplantation (Arm A), or SCT alone (Arm B). Surgery for complete resection was scheduled as soon as feasible. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS) and safety. RESULTS: From September 2009 to November 2016, 44 patients were randomised (A:22; B:22). In total, 54.5% were males, and the median age was 16 years (9-32years). The two-year OS rate was 66.7% (95% CI 42.5-82.5) (SCT + HDTp, Arm A) versus 50.0% (95% CI 28.2-68.4) for SCT alone (Arm B). Median OS was 27.4 and 24.8 months, respectively (hazard ratio [HR] 0.826, 95% CI 0.393-1.734; p = 0.6123). Median PFS was 15.6 (8.9-24.9) months in Arm A versus 7.2 (4.8-33.3) months in Arm B, p = 0.3845. Among the 22 patients treated with SCT + HDTp, 16 (72.7%) experienced at least one grade ≥3 adverse events versus 18/22 (81.8%) patients treated with SCT. No toxic death occurred. CONCLUSION: Adjuvant HDTp failed to significantly improve OS and PFS in resectable relapsed osteosarcomas. Despite a trend of prolonged survival and an acceptable toxicity, thiotepa cannot be recommended. KEY MESSAGE: HDTp and autologous transplantation added to SCT did not improve OS and PFS in patients with resectable relapsed osteosarcomas. Despite a trend of prolonged survival, thiotepa cannot be recommended.
引用
- Marec-Berard P, Dalban C, Gaspar N, et al. A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma. Eur J Cancer. 2019. PMID: 31838406. doi:10.1016/j.ejca.2019.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。